News
Quantum technology and cancer. Research and application in its detection and treatment
The Centre de Cultura Contemporània of Barcelona (CCCB), with the collaboration of the Bellvitge Biomedical Research Institute (IDIBELL) and the program of Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), organized last 25th June 2019 a conference at the CCCB called “Quantum Technology and Cancer. Research and application in its detection and treatment.” In this interactive […]
Brain structure determines individual differences regarding music sensitivity
The white matter structure in the brain reflects music sensitivity, according to a study by the research group on Cognition and Brain Plasticity of the Institute of Neurosciences of the University of Barcelona (UB) and the Bellvitge Biomedical Research Institute (UB-IDIBELL). The study, published in Journal of Neuroscience, shows that white matter connectivity, the tissue […]
Tractivus raises 431,000 euros and consolidates its growth
The company will soon initiate preclinical validation tests of its implantable medical devices
Distinct clinical profiles of Huntington’s disease can be associated with two specific neural signatures
Cognitive-motor and psychiatric profiles of Huntington’s disease show a different pattern of brain alterations
Researchers identify an amino acid transporter as responsible for the onset of congenital cataracts
The ‘human molecular genetics’ research group of the Bellvitge Biomedical Research Institute, led by Dr. Virginia Nunes (IDIBELL – UB – CIBERER), has participated in a research study demonstrating that the amino acid transporter LAT2 causes congenital cataracts in both animals and humans. This study, published in Frontiers in Physiology, has discovered that LAT2 ablation causes […]
Fundación Mey Hofmann, al lado de las mujeres con cáncer de mama
La Fundación nace con un acuerdo de colaboración con el IDIBELL (Instituto de Investigación Biomédica de Bellvitge) y el ICO (Institut Català d’Oncología)
Mey Hofmann Foundation, next to women with breast cancer
The Foundation is born with a collaboration agreement with the IDIBELL (Bellvitge Biomedical Research Institute) and the ICO (Catalan Institute of Oncology)
IDIBELL researchers relate the amplification of a chromosomal region with resistance to a chemotherapeutic drug in breast cancer
Scientists propose a new way to face this resistance and a first biomarker to predict if it could appear or not
A dietary supplement improves the motor and communicative skills of a patient with atypical Rett syndrome
Administration of the amino acid L-serine, a dietary supplement, contributes to the improvement of the communicative and motor skills of a patient with a mutation that affects glutamate receptors